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Abstract
Background: Visceral leishmaniasis (VL) is a protozoan disease, which is responsible for 200.000–400.000 yearly
infections worldwide. If left untreated, the fatality rate can be as high as 100% within 2 years. 90% of cases occur
in just six countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil. It is thus a disease rarely seen by
physicians in Europe or North America. We report on the fatal case of VL in an 80-year-old immunosuppressed
patient who presented with a latency of over 15 years after having visited an endemic region. This is the first report
showing such extreme latency of VL in a European traveller. This case is furthermore unusual because it suggests
primary treatment failure to liposomal amphotericin B.
Case presentation: An 80-year-old man who was on immunosuppressive treatment due to a non-specific
inflammatory disease of the liver and kidney presented to our hospital with recurrent fever, fatigue and bloody
diarrhoea. Histopathological analysis from a colon biopsy showed intracellular amastigotes. The diagnosis of VL
was confirmed by polymerase-chain-reaction (PCR) of the colon biopsy. PCR was also performed in plasma,
a bronchopulmonary lavage, a lymph node, liver and bone marrow biopsy and proved L. donovani as causative
species. The disseminated infection was unresponsive to treatment with liposomal amphotericin B as
recommended in immunosuppressed individuals despite stopping immunosuppressive treatment.
Conclusion: Imported cases of VL to non-endemic regions are increasing due to extensive international travel
and migration. Furthermore, the increase of elderly patients and immunosuppressed individuals, secondary to HIV,
post-transplant and chemotherapeutic agents, has resulted in an increase of VL also in endemic regions of Europe.
It is thus important for physicians to be able to recognize the infection. This case also demonstrates treatment
failure to amphotericin B, which was only a known problem in patients with HIV until now. The knowledge of this
as a possible complication is important for specialists treating the disease.
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Background
Visceral leishmaniasis (VL; also known as “kala-azar”) is
a neglected parasitic disease caused by the protozoans
Leishmania donovani and L. infantum. Worldwide 0,2
to 0,4 million new clinical cases are diagnosed annu-
ally, 90% of these occurring in just six countries:
India, Bangladesh, Sudan, South Sudan, Ethiopia and
Brazil [1, 2].
Leishmania parasites are transmitted through the bites
of female sand-flies (genus Phlebotomus in the Old
World and Lutzomyia in the New World) and multiply
in different macrophage populations in the human host.
Fever, splenomegaly, pancytopenia, consuming weight
loss, and weakness are the main clinical features. VL is
fatal if left untreated.
Today, the first line treatment for immunocompe-
tent patients is liposomal amphotericin B, although
various regimens are used in different endemic regions
[3–5]. Regarding the treatment of immunosuppressed
individuals, evidence-based treatment recommendations
are currently limited to human immunodeficiency virus
(HIV) positive patients. HIV-coinfection has been
reported to increase the risk of treatment failure, relapse
and mortality [6]. The World Health Organisation
(WHO) equally recommends liposomal amphotericin B
for these patients, yet with a higher cumulative dose of
40 mg/kg [5].
Here we report the fatal case of an 80-year-old
immunosuppressed patient presenting with VL more
than 15 years after having visited an endemic region and
despite treatment with liposomal amphotericin B as
recommended in immunosuppressed individuals.
Case presentation
An 80-year-old man presented to our hospital in March
2015 with recurrent fever, fatigue and bloody diarrhoea.
Clinical examination revealed a patient in sepsis with
hypotension (86/64 mmHg), tachycardia (115/min), fever
of 38.6 °C, bibasal crepitations, hepatosplenomegaly, and
a bodyweight of 76 kg.
Laboratory examinations showed leucopenia of 3.1 G/l
(reference range 3.5–10.5), normal haemoglobin and
platelets, elevated liver enzymes with ASAT 60 U/l (<50)
and ALAT 71 U/l (<50), and altered kidney function
with creatinine 183 μmol/L (59–104) and a glomerular
filtration rate of 29 ml/min (>59).
The patient had already been evaluated for elevated
liver enzymes in 2009 with a biopsy showing a non-
specific granulomatous inflammation. After finding no
evidence for tuberculosis and sarcoidosis he was inter-
mittently treated for an unspecified inflammatory liver
disease with high dose corticosteroids, azathioprine and
mycophenolate mofetil without any apparent improve-
ment (Fig. 1). When the kidney function deteriorated
during treatment a kidney biopsy was performed in
2013. Again, histological examination showed a non-
specific granulomatous inflammation. As further exami-
nations by the nephrology department revealed no
specific cause, immunosuppressive treatment with high-
dose corticosteroids and azathioprine was continued and
was still on-going when he presented in March 2015.
The medical history was otherwise unremarkable
except for treated hypertension, diabetes mellitus type II,
surgery for an abdominal aneurysm and treated Q-fever
in 1984. The patient was born in Holland and moved to
Fig. 1 Timeline demonstrating the course of disease from first symptoms, intermittent treatment with immunosuppressive medication, to diagnosis of
visceral leishmaniasis
Eichenberger et al. BMC Infectious Diseases  (2017) 17:81 Page 2 of 5
Switzerland as an adult. He had extensively travelled
when working abroad as an engineer with longer stays
till 1995 in Sudan, Bangladesh, Suriname and Indonesia.
His last shorter journeys were to Indonesia and India in
2000. Since then, he had only regularly travelled to
Sardinia.
Numerous serologic investigations were done with no
pathological findings, including a negative HIV test and
negative serologies for histoplasmosis and coxiella (the
latter with IgG positive but IgM negative). Due to the
bloody diarrhoea a colonoscopy was performed, showing
extensive colitis. Histopathological analysis of the biopsy
revealed intracellular amastigotes in very high density
(Fig. 2). The diagnosis of VL was supported by a strongly
positive serology and finally confirmed by polymerase
chain reaction (PCR) from the colon biopsy as well as
plasma, confirming L. donovani as causative species.
Following the diagnosis, treatment with azathioprine
was stopped immediately and the corticosteroids were
slowly tapered. Treatment with liposomal amphotericin
B was started with a dose of 3 mg/kg/day on days 1–5,
14, 21, and weekly thereafter. However, the patient’s
condition continued to deteriorate with on-going fevers,
wasting and progressive weakness. Further investigations
were conducted to exclude any other pathology. A
bronchopulmonary lavage, a lymph node biopsy, a re-
peated liver biopsy and two bone marrow biopsies were
again PCR-positive for L. donovani but showed no other
pathologies. A positron emission tomography–computed
tomography (PET-CT) showed enhancement through-
out the colon, spleen, liver, lymph nodes and basal
compartments of the lungs (Fig. 3), again underlining
the dissemination and severity of the disease. The patient
also developed several complications during treatment,
such as severe hypercalcaemia, gram-negative catheter-
associated bacteremia, and an acalculous cholecystitis,
though all could be controlled.
In order to monitor the treatment, real-time PCR from
plasma was conducted before treatment, as well as one
and two months after treatment initiation. However, the
cycle threshold remained at the same value throughout
the treatment course, suggesting no response to treat-
ment. Despite receiving a cumulative dose of 40 mg/kg
liposomal amphotericin B, the patient died shortly after
completing treatment in July 2015, only 12 weeks after
the diagnosis was made.
Discussion
This is a case of VL in an elderly immunosuppressed
patient diagnosed with an extraordinary long latency of
more than 15 years after exposure. Due to the geo-
graphical distribution of L. donovani, the patient must
have acquired the disease in either India, Sudan or
Bangladesh, where he had travelled last before 2000
(India) and 1995 (Sudan and Bangladesh) [2]. In Europe
L. donovani has recently been described only in Cyprus,
however never in Sardinia [7]. This extreme latency
and the fact that he only developed the classical
hallmarks of the disease late into the course of his
infection (hepatosplenomegaly and weight loss a few
months and pancytopenia a few weeks before his death)
certainly severely hampered and delayed the diagnostics
Fig. 2 Histological preparation of colon biopsy, showing innumerable intracellular amastigotes in lamina propria macrophages (Giemsa staining,
x500) and magnified section showing three enlarged macrophages (x1000)
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(Fig. 1). In retrospect, the granulomatous inflammation,
which had already been discovered in his liver biopsy in
2009 and his kidney biopsy in 2013, is well explained by
VL. However, when retrospectively re-evaluating these
earlier biopsies, no amastigotes were detectable. In 2015,
parasitic infiltration was seen in his bone marrow, lymph
nodes, colon, spleen, liver, kidneys and lung. There are
case reports of VL involving unusual sites like the lung,
the colon and the kidneys and VL-related cholecystitis has
also been reported [8]. However, it is unusual for VL to
manifest in as many organs as in our patient. This can be
explained by the long-standing infection and prolonged
immunosuppressive therapy.
Initially, when the treatment induced no clinical im-
provement and other chronic infectious diseases (such
as tuberculosis, histoplasmosis or Q-fever) had been
excluded after extensive diagnostic work-up, we specu-
lated that this could be due to stopping azathioprine and
tapering corticosteroids - in an immune condition
similar to the immune reconstitution inflammatory
syndrome (IRIS) known in acquired immunodeficiency
syndrome (AIDS) patients. However, intermittent treat-
ment with methylprednisolone did not change the
clinical course. Due to the hypercalcaemia (albumin-
corrected max 3,67 mmol/L), we also discussed the
development of a macrophage activation syndrome, though
this could not be confirmed in bone marrow biopsies.
The further differential was treatment failure due to a
very high parasite burden in a patient with multiple risk
factors (age, long immunosuppression and potentially
several years of untreated disease). The parasite burden
was certainly immense, which was shown in the histo-
logical preparation of the colon biopsy (Fig. 2) and
highlighted in the PET-CT (Fig. 3).
In immunocompetent patients, treatment with lipo-
somal amphotericin B usually leads to rapid clinical
improvement and cure. Our patient failed to improve
clinically, even though his cumulative dosage of lipo-
somal amphotericin B was adjusted for immunocom-
promised patients and his immunosuppressive treatment
had been stopped [5]. The cycle threshold of the real-
time PCR remained stable for all samples. Although
the real-time PCR used in our investigation is not a
validated quantitative method, this finding together
with his rapidly deteriorating clinical condition sug-
gested primary treatment failure. Using an ultrasensi-
tive real-time PCR has been shown to be a useful
tool in monitoring treatment success and relapses of
visceral leishmaniasis in HIV-infected patients [9]. Li-
posomal amphotericin B is generally the most effect-
ive and best tolerated treatment for VL. Relapses are
extremely rare in immunocompetent patients, but are
a known problem in HIV-positive and solid organ trans-
plant patients [6]. Resistance to liposomal amphotericin B
had not been described until a recent publication re-
ported unresponsiveness to liposomal amphotericin B
in 4 patients (1 immunocompetent, 3 immunosuppressed)
[10]. Administering pentavalent antimony cured these
patients.
For patients similar to ours a combination treat-
ment could be an alternative, although there is cur-
rently not enough international data to judge the
value of this approach [11]. However, studies in India
have demonstrated excellent efficacy of short combin-
ation therapy and according to expert opinion, com-
bination therapy will probably become the standard of
VL treatment in the future which will allow to
shorten treatment regimens, thus reducing treatment
related toxicity, as well as preventing emergence of
drug resistance [12]. Combination therapy may hope-
fully also be able to prevent relapses and failure of
monotherapy in immunocompromised patients as
described in this case report.
Fig. 3 Transverse images of 18 F-FDG PET-CT showing intense
uptake of FDG into (a) pleural base, (b) the enlarged spleen (18 cm)
and (c) colon and peritoneal lymph nodes
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Conclusion
International travelling has led to an increase of
imported leishmaniasis (though mainly cutaneous forms)
in non-endemic countries, making the recognition of
this parasitic infection important, especially since many
physicians are not familiar with this disease [13].
Furthermore, the increase of elderly patients and im-
munosuppressed individuals, secondary to HIV, post-
transplant and chemotherapeutic agents, has resulted in
an increase of VL in L. infantum-endemic regions of
Europe [2, 14]. On top, unusual clinical presentations of
VL may hamper the timely diagnosis in these individ-
uals. Therefore, VL should always be included in the
differential diagnosis, especially in patients with a travel
history to endemic areas several decades ago and not
presenting initially with the cardinal symptoms of
the disease.
Patients requiring prolonged treatment with immuno-
suppressant drugs should undergo a detailed history of
travel prior to the start of the medication, and tests
investigating tuberculosis and tropical diseases such as
leishmaniasis and strongyloides should be considered.
The mainstay of therapy for VL is still liposomal
amphotericin B in immunocompetent patients. However,
specialists have to be aware of treatment failure as a rare
complication, even in immunocompetent patients, when
treating the disease. Although the evidence is currently
limited to a case series, salvage therapy with pentavalent
antimony should be considered in patients failing to
respond to amphotericin B [10].
Abbreviations
FDG PET-CT: Fluorodeoxyglucose positron emission tomography combined
with CT; HIV: Human immunodeficiency virus; PCR: Polymerase chain
reaction; VL: Visceral leishmaniasis
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
AE drafted the paper and contributed to the content of the manuscript.
AEB made an overview of the clinical presentation of the patient and helped
to draft the manuscript. AN and CH critically reviewed the paper. AR and
MH contributed to the content of the manuscript. EDK and AN provided
the histopathological images. CS contributed to the literature review and
critically reviewed the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the daughter of the patient for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor of this journal.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Infectious Diseases, Bern University Hospital (Inselspital),
University of Bern, PKT2B, CH-3010 Bern, Switzerland. 2Swiss Tropical and
Public Health Institute, Basel, Switzerland. 3University of Basel, Basel,
Switzerland. 4Department of Nephrology, Bern University Hospital
(Inselspital), University of Bern, Bern, Switzerland. 5Institute of Pathology,
University of Bern, Bern, Switzerland.
Received: 10 September 2016 Accepted: 5 January 2017
References
1. Leishmaniasis Fact sheet N°375. [http://www.who.int/mediacentre/
factsheets/fs375/en/]. Accessed 14 Mar 2016.
2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M,
Team WHOLC. Leishmaniasis worldwide and global estimates of its incidence.
PLoS One. 2012;7(5):e35671.
3. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN,
Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, et al. Liposomal amphotericin B
for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43(7):917–24.
4. Monge-Maillo B, Lopez-Velez R. Therapeutic options for visceral leishmaniasis.
Drugs. 2013;73(17):1863–88.
5. WHO (2010). Control of the leishmaniases. Report of a meeting of the WHO
Expert Committee on the control of leishmaniases; Geneva, 22–26 March
2010. WHO technical report series no. 949. Geneva, Switzerland: World
Health Organization.
6. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis
in immunosuppressed individuals. Clin Microbiol Infect. 2014;20(4):286–99.
7. Antoniou M, Gramiccia M, Molina R, Dvorak V, Volf P. The role of indigenous
phlebotomine sandflies and mammals in the spreading of leishmaniasis
agents in the Mediterranean region. Euro Surveill. 2013;18(30):20540.
8. Cermano JR, Caraballo AJ, Gonzalez J. Acalculous cholecystitis in a patient
with visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2001;95(6):621–2.
9. Molina I, Fisa R, Riera C, Falco V, Elizalde A, Salvador F, Crespo M, Curran A,
Lopez-Chejade P, Tebar S, et al. Ultrasensitive real-time PCR for the clinical
management of visceral leishmaniasis in HIV-Infected patients. AmJTrop
Med Hyg. 2013;89(1):105–10.
10. Morizot G, Jouffroy R, Faye A, Chabert P, Belhouari K, Calin R, Charlier C,
Miailhes P, Siriez JY, Mouri O, et al. Antimony to Cure Visceral Leishmaniasis
Unresponsive to Liposomal Amphotericin B. PLoS Negl Trop Dis.
2016;10(1):e0004304.
11. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical
practice guidelines review. Curr Opin Infect Dis. 2015;28(5):426–37.
12. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis.
Expert Opin Pharmacother. 2015;16(2):237–52.
13. Field V, Gautret P, Schlagenhauf P, Burchard GD, Caumes E, Jensenius M,
Castelli F, Gkrania-Klotsas E, Weld L, Lopez-Velez R, et al. Travel and
migration associated infectious diseases morbidity in Europe, 2008.
BMC Infect Dis. 2010;10:330.
14. Okwor I, Uzonna JE. The immunology of Leishmania/HIV co-infection.
Immunol Res. 2013;56(1):163–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Eichenberger et al. BMC Infectious Diseases  (2017) 17:81 Page 5 of 5
